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This report updates patient and primary graft sur-
vival statistics for the liver transplantation program at 
the University of Pittsburgh for 1984 through 1990. 
Minimum follow-up for all patients is one year and only 
patients who received a primary liver graft in Pittsburgh 
are included. Recipients of multiple organ ormultMsceral 
transplants, patients who received a primary graft at 
another center and were sent to Pittsburgh for rescue 
with FK506 or for retransplantation, and patients who 
underwent an extended resection ("cluster operation") 
for cancer were excluded. 
METHODS 
DEMOGRAPHICS 
Time Periods and Treatment Protocols. 
The liver transplant program at the University of 
Pittsburgh was established in 1981. Data are presented 
for three time periods (Table 1) which correspond to 
major changes in treatment protocols. In the first three 
years of the program, protocols for immunosuppres-
sion with cyclosporine (CsA) and prednisone (Pred) 
were refined, the veno-venous bypass technique for 
management of the an hepatic phase of the recipient 
operation was developed, and the techniques of mUl-
tiple organ procurement from cadaveric donors using 
Euro-Collins and ice slush preservation were standard-
ized. In 1984, we began using OKT3 monoclonal anti-
body (Orthoclone OKT38 , , Ortho Pharmaceuticals) for 
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Period N % 
1184-9187 CsA. vein bvDass. OKT·3 787 37.7% 
10187·12188 UWsolution 481 23.0% 
1/89·12190 FK506 822 39.3% 
Total 2090 100.0% 
treatment of steroid resistant acute allograft rejection, 
after Cosimi and his associates at the Massachusetts 
General Hospital demonstrated its effectiveness forthe 
treatment of acute renal allograft rejection. These pro-
tocols remained the essentials of patient management 
in Pittsburgh for the period from 1984 through Septem-
ber, 1987, during which time 787 patients received a 
primary liver transplant. Of these patients, 573 (72.8%) 
ultimately received only one graft, 163 (20.7%) re-
ceived two grafts, and 51 (6.5%) required three or more 
grafts. As of December 31, 1991, there were 480 
(61.0%) surviving patients including 396 (50.3%) with a 
functioning first graft. 
In October, 1987, we began the regular use of the 
University of Wisconsin solution instead of Euro-Collins 
for liver preservation. Between October, 1987 and 
December, 1988 there were 481 recipients of a primary 
liver graft in Pittsburgh under CsA-Pred therapy. 
Among these patients, 390 (81.1 %) received only 
one graft, 70 (14.6%) received two grafts, and 21 
(4.4%) received three or more grafts. As of December 
31, 1991, there were 331 (68.8%) surviving patients 
including 292 (60.7%) with functioning first grafts. 
Experimental trials with FK506 began in 1989. From 
January, 1989 through December, 1990,822 patients 
received liver transplants, including 684 (83.2%) who 
required only one graft to date, 120 (14.6%) who 
received a second graft, and 18 (2.2%) who have 
received three or more grafts. As of December 31, 
1991, there were 650 (79.1 %) surviving patients includ-
ing 577 (70.2%) surviving with their first graft. 
In the entire series of 2,090 patients, 1,633 (78.1 %) 
were transplanted using the CsA-Pred regimen 
(Table 2), but 272 were eventually switched to FK506, 
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Table 2. Immunosuppressive protocol 
Period 1 Period 2 
Primary FK 506 
Rescue FK 506 99 29 
12.6% 6.0% 
Randomized trial* 
Primary GsA 688 452 
87.4% 94.0% 
Total 787 481 
Period 3 
399 
103 
12.5% 
112 
13.6% 
208 
25.3% 
822 
Total 
399 
19.1% 
231 
11.1% 
112 
5.4% 
1348 
64.5% 
2090 
Age Groups and Body 
Weight 
·Includes 54 patients randomized to CsA and 58 patients randomized to FK 506. 
The distribution of pa-
tients according to age is 
shown in Table 3. There 
has been an increase in 
the proportion of elderly pa-
tients(over60yearsofage) 
accepted for transplanta-
tion since 1984 from 5.7% 
ofthe patients in period 1 to 
16.0% of the patients in 
period 3. The proportion of 
infants receiving trans-
plants has remained fairly 
constant. Survival rates 
for 208 small patients (un-
der 12 kg) and 21 obese 
patients(over115 kg) were 
compared with survival 
rates for 1 ,383 adults be-
tween 50 and 115 kg .. 
Table 3. Age Groups 
Period 1 Period 2 
Infants 63 45 
(under 2 yrs) 8.0% 9.4% 
Children 171 40 
(2 - 11 yrs) 21.7% 8.3% 
Adolescents 37 9 
(12-17 yrs) 4.7% 1.9% 
Adults 471 333 
(18-59 yrs) 59.8% 69.2% 
Seniors 45 54 
(over 60 yrs) 5.7% 11.2% 
Total 787 481 
Table 4. Medical urgency 
Period 2 Period 3 Total 
Elective 26 17 43 
5.4% 2.1% 3.3% 
Out of hospital 94 89 183 
19.6% 10.8% 14.1% 
In hospital 216 304 520 
45.1% 37.0% 40.0% 
Critical 143 412 555 
29.9% 50.1% 42.7% 
Total 479 822 1301 
including 41 of 54 patients who were transplanted un-
der CsA-Pred in 1990 as part of a randomized trial 
comparing CsA-Pred to FK506. Another 103 of the 311 
patients in period 3 who were transplanted under CsA-
Pred, but were not part of the randomized trial, were 
also converted to FK506. Approximately 5 to 1 0 percent 
of the patients per year who received a primary graft 
under CsA-Pred during periods 1 and 2 have been 
converted to FK 506. 
Period 3 
59 
7.2% 
46 
5.6% 
23 
2.8% 
562 
68.4% 
132 
16.0% 
822 
Total 
167 
8.0% 
257 
12.3% 
69 
3.3% 
1366 
65.4% 
231 
11.1% 
2090 
Medical Urgency 
Table 4 presents the dis-
tribution of patients in peri-
ods 2 and 3 according to 
patient condition at the time 
of transplantation. There 
has been a substantial increase in the percentage of 
patients at this center in critical condition at the time of 
transplantation. 
Primary liver disease 
Distribution of the most common primary indications 
for liver transplantation for each period is shown in 
Table 5. The most significant changes were the relative 
decrease in the percentage of adult patients with pri-
mary biliary cirrhosis and the increase in the percentage 
of patients with alcoholic cirrhosis. 
STATISTICAL METHODS 
Actuarial survival 
Survival out to 5 years after transplantation is pre-
sented in a series of actuarial survival plots. Most of the 
cohorts analyzed for this report are large (over 100 
patients) and therefore suitable for analYSis by the life-
table method in which survival is determined over 
predefined time intervals (1, 3, 6, and every 6 mos 
thereafter out to 60 mos). Life-table data are presented 
as a plot of the estimated survivor function (the probabil-
3 
Table 5 Most common pnmary liver diseases 
Period 1 Period 2 Period 3 Total 
% % % % 
Fulminant hepatic failure 36 4.6 33 6.9 54 2.9 93 4.5 
Postnecrotic cirrhosis 222 28.2 140 29.1 280 34.1 642 30.7 
Cryptogenic cirrhosis" 166 21.1 83 17.3 1n 21.5 426 20.4 
HBsAg+ cirrhosis 27 3.4 34 7.1 53 6.4 114 5.5 
Autoimmune CAH 17 2.2 16 3.3 25 3.0 58 2.8 
Alcoholic cirrhosis 39 5.0 69 4.3 167 20.3 275 13.2 
Biliary atresia 152 19.3 52 10.8 81 9.9 285 13.6 
Primary biliary cirrhosis 123 15.6 59 12.3 66 8.0 248 11.9 
Sclerosing cholangitis 55 7.0 36 7.5 55 6.8 146 7 
Genetic disorders 72 9.1 27 5.6 33 4.0 132 6.3 
Alpha-1-antitrypsin deficiency 40 5.1 13 2.7 18 2.2 71 3.4 
Wilson's disease 13 1.7 7 1.5 5 0.6 25 1.2 
Primary liver cancer 20 3.2 32 6.7 58 7.1 110 5.3 
.. includes all non-A, non-B fonns of viral hepatitis and cryptogenic cirrhosis in HBsAg- patients 
ity that a subject will survive to at least a specified time 
or longer) and as a plot of the cumulative hazard 
function (negative natural logarithm of the estimated 
survivor function). In the few series in which the number 
of cases was small, we used the product-limit (Kaplan-
Meier) method of computation for the survivor function. 
Observed (actual) Survival 
This year the National Organ Sharing Network 
(UNOS) will release center-specific survival data (ob-
served 3- and 12-month patient and primary graft 
survival rates) for transplantations performed between 
October 1, 1987 and December 31, 1989. The ob-
served survival rate is simply the proportion of patients 
who survive to a specified cut point. Since follow-up for 
our series was complete and all patients were followed 
for at least 1 year, the 3- and 12-month estimated 
survivor functions determined by life-table calculation 
and by observed survival rate calculation should be 
identical. Figure 1 compares observed and actuarial 
patient and primary graft survival rates for each of the 
3 periods at 3 and 12 months. 
Statistical significance 
Statistical significance between observed survival 
rates was determined using the chi-square statistic. 
For comparison of life-table survival curves, Breslow, 
Mantel-Cox, Peto, and Tarone-Ware statistics were 
calculated. Differences were considered statistically 
significant if p was less than 0.05. 
RESULTS 
Time Periods 
There has been a significant improvement in patient 
survival over the periods analyzed. Figures 2 and 3 
present the life-table analysis plots for patient and 
primary graft survival by period. Table 6 shows the 
observed 3- and 12-month patient and primary graft 
survival rates. The life-table plots demonstrate that 
most of the mortality after liver transplantation (12-
21 %) occurs within the first 3-months 
posttransplantation. The 3-month observed patient 
survival rate improved from 78.9% in period 1 to 88.7% 
in period 3. The 12-month patient survival rate improved 
from 72.3% in period 1 to 83.1 % in period 3. 
Immunosuppressive Protocol 
Table 7 presents the observed survival rates for 
399 patients who received a transplant under an FK506 
protocol, 391 historical control patients from period 2 
who received transplants under a CsA protocol, and 
161 patients converted from CsA to FK506. Survival 
rates under the FK506 protocol improved over those 
obtained for the historical CsA protocol controls. The 
differences in patient survival at 3 months and at 12 
months between the FK506 treated patients and the 
CsA treated historical controls are highly significant 
(p < 0.01). The differences between the 2 groups for 
first graft survival at 3 and 12 months were significant 
(p< 0.02). 
The rescue series included aU patients who re-
tained their first grafts and were converted to FK506 
prior to January 1, 1991. The observed survival rates 
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were calculated from the time of crossover to FK506. 
There is a high rate of successful patient and graft 
rescue out to 12 months after crossover. 
Results of the randomized trial comparing FK506 
and GsA were presented recently by Fung et al1 and are 
not included here. 
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Table 6. Observed patient and graft survival rates by period 
Period 1 Period 2 
Surviving Lost Surviving Lost 
3 -month patient* 621 166 400 81 
78.9% 21.1% 83.2% 16.8% 
12-month patient* 569 218 366 115 
72.3% 27.7% 76.1% 23.9% 
3-month first graft* 548 239 363 118 
69.6% 30.4% 75.5% 24.5% 
12-month first graft* 491 296 331 150 
62.4% 37.6% 68.8% 31.2% 
*p < 0.001 
5 
Period 3 
Surviving Lost 
729 93 
88.7% 11.3% 
683 139 
83.1% 16.9% 
654 168 
79.6% 20.4% 
604 218 
73.5% 26.5% 
Table 7. Observed patient and graft survival rates - immunosuppression 
Primary FK 506 Historical CsA* After FK 506 rescue** 
Surviving Lost Surviving Lost Surviving Lost 
3 -month patient 358 41 318 73 151 10 
89.7% 10.3% 81.3% 18.7% 93.8% 6.2% 
12-month patient 333 66 291 100 138 23 
83.5% 16.5% 74.4% 25.6% 85.7% 14.3% 
3-month first graft 327 72 294 97 144 17 
82.0% 18.0% 75.2% 24.8% 89.4% 10.6% 
12-month first graft 304 95 266 125 132 29 
76.2% 23.8% 68.0% 32.0% 82.0% 18.0% 
* 391 patients treated with CsA-Pred in period 2 (10/87-12/88) 
**Observed sUlVival rates after rescue with FK 506 
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Age Group and Body Weight 
There were significant differences in survival rates 
among patients in different age groups and significant 
improvements in survival rates for most age groups 
across the 3 time periods. Figures 4 and 5 present the 
life-table plots for patient and primary graft survival by 
age groups. Table 8 shows the observed 3- and 12-
month patient and primary graft survival rates. Survival 
rates for infants have been generally lower than for 
older children and adults, but in period 3, infant survival 
rates attained parity. Early survival rates for patients 
over 60 compared favorably with those for younger 
adult patients, but, as would be expected, for older 
patients there was a modest increase in the rate of 
patient loss over the longer term. 
In Figure 6 the estimated survivor and cumulative 
hazard functions (Kaplan-Meier method) were stratified 
into 3 weight groups, under 12 kg (small), 50-115 kg 
(normal adults), and over 115 kg (obese). Survival rates 
for small and obese patients were significantly lower 
than those for normal weight adult patients. 
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Medical Urgency 
Table 9 presents the observed patient and graft 
survival rates and Figure 7 presents the estimated 
patient survivor and cumulative hazard functions after 
liver transplantation according to patient condition the 
time of transplantation. A significant penalty is demon-
strated for patients in high urgency status at the time of 
transplantation. 
Primary Liver Disease 
Tables 10 through 12 show the observed 3- and 
12-month patient and primary graft survival rates for 
each time period according to primary liver disease. 
_-NormoI (&0-115 kg) 
_0bMe(>1151cg) 
""""_«12 kg) 
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Table 9. Observed patient and graft survival rates by medical urgency 
Elective Out of hospital In hospital Critical 
Survivine Lost Surviving 
3 -month patient 56 1 171 
98.2% 1.8% 88.6% 
12-month patient 54 3 167 
94.7% 5.3% 86.5% 
3-month first graft 54 3 154 
94.7% 5.3% 79.8% 
12-month first graft 49 8 148 
86.0% 14.0% 76.7% 
Based on 1.345 patients from periods 2 and 3. 
Figures 8 and 9 illustrate the estimated survivor and 
cumulative hazard functions for patient and primary 
graft survival for patients with postnecrotic cirrhosis 
(excluding HBsAg+ patients), adult cholestatic liver 
disease (primary biliary cirrhosis and primary scleros-
ing cholangitis), biliary atresias, and alcoholic cirrhosis. 
Figures 10 and 11 present the life-table functions for 
patient and primary graft survival for patients with 
fulminant failure, chronic active hepatitis B (HBsAg+ 
patients), and primary liver cancer (mostly hepatomas). 
As mentioned earlier, overall results for the most 
recent period have improved significantly over earlier 
results. The most dramatic improvements in survival 
rates were seen in patients receiving liver transplants 
for fulminant hepatic failure, chronic active hepatitis B, 
biliary atresia, and primary sclerosing cholangitis. I n the 
case of fulminant hepatiC failure, new protocols for 
monitoring of intracerebral blood flow and prevention of 
excess intracranial pressure were probably responsible 
..... -E_tNoo57) 
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Lost Survivine Lost Surviving Lost 
22 482 50 481 102 
11.4% 90.6% 9.4% 81.9% 18.1% 
26 451 81 415 148 
13.5% 84.8% 15.2% 73.7% 26.3% 
39 440 92 403 160 
20.2% 82.7% 17.3% 71.6% 28.4% 
45 398 134 366 197 
23.3% 74.8% 25.2% 65.0% 35.0% 
for the improved results. In biliary atresia, technical 
improvements in arterial reconstruction, increased use 
of reduced grafts to find organs for smaller children, and 
improved immunosuppression with FK506 protocols 
may have all contributed to the improvements. For 
chronic active hepatitis B, immunoprophylaxis, includ-
ing both active and passive immunization, and a re-
duced requirement for steroids in patients receiving 
FK506 may have a beneficial effect. Earlier referral of 
patients, decreasing technical difficulties in performing 
liver transplantation in patients with prior surgery (in-
cluding biliary diversion or prior bowel resection), and 
improvements in immunosuppression have probably 
contributed to the improved results for patients with 
sclerosing cholangitis. 
We continue to offer liver transplantation to patients 
with alcoholic cirrhosis and to obtain results which 
compare favorably to those obtained in patients with 
other forms of postnecrotic cirrhosis. 
---
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Cryptogenic cirrhosis· 
HBsA(JI- cirrhosis 
Autoimmune CAH 
cln1losls 
Cryptogenic cirrhosis· 
HBsA(JI- cirrhosis 
Autoimmune CAH 
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New protocols for liver transplantation for primary 
cancer which have been instituted in our program have 
not yet been analyzed and are not presented here. 
Iwatsuki et al2 recently summarized our experience for 
1980-1989 with hepatocellular carcinoma in a report 
which favorably compared results for liver transplanta-
tion with hepatic resection. The reader is advised to 
consult this paper for additional information. 
CONCLUSION 
Survival after liver transplantation continues to im-
prove, reflecting continuing advances in surgical meth-
ods, organ preservation, and immunosuppressive pro-
tocols. At the present time, the Health Care Financing 
Administration (Medicare) has approved liver trans-
plantation for biliary atresia in children and for 
postnecrotic cirrhosis (except for HBsAg+ patients), 
alcoholic cirrhosis, primary sclerosing cholangitis, pri-
mary biliary cirrhosis, alpha-1-antitrypsin deficiency, 
Wilson's disease, and hemochromatosis in adults. Liver 
transplantation for fulminant hepatic failure and for 
chronic active hepatitis B has not yet been approved. 
Given the improved results now being obtained, expan-
sion of the approved indications for liver transplantation 
to include fulminant hepatiC failure and chronic active 
hepatitis B seems warranted. 
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SUMMARY 
Patient and primary graft survival for 2,090 pa-
tients who received primary liver transplants at the 
University of Pittsburgh from 1984 through 1990 are 
presented. Observed (actual) 3- and 12-month pa-
tient and first graft survival rates were compared for 
three time periods: 1) January, 1984 -September, 
1987 (cyclosporine, OKT3, and Euro-Collins pres-
ervation period); 2) October, 1987 - December, 
1988 (University of Wisconsin solution preservation 
period); and 3) January, 1989 - December, 1990 
(FKS06 period). Data for results according to age 
group, medical urgency, and primary diagnosis are 
provided. In addition, estimated survivor and cumu-
lative hazard functions (Iife-tanle method) for pa-
tient and first graft survival out to 60 months after 
transplantation are presented. 
Overall results have improved significantly in 
recent experience. Most notable are the improved 
results seen in liver transplantation for patients with 
biliary atresia (especially in infants), primary scle-
rosing cholangitis, fulminant hepatic failure, and 
chronic active hepatitis B. For all but a few condi-
tions, most of the mortality after liver transplantation 
occurs in the first three months after surgery. Less 
than 2% of patients are lost in each 6-month interval 
beyond the first 6 months after transplantation. 
Outcome is related to patient condition at the 
time of transplantation. Observed patient survival 
rates at 3 and at 12 months for patients called in to 
the hospital to receive a graft were 88.6% and 
86.S%, respectively, compared to 81.9% and 73.7% 
for patients in critical condition. The continuing 
shortage of organs for transplantation, which often 
forces patients to wait longer for an organ than they 
can afford to, continues to impose a significant 
penalty. 
